drugset / Trial / NCT06361875
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2025-06-09
- Completion
- 2025-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Flublok Quadrivalent | Vaccine | — | Intramuscular |
| Comparator | Fluzone High-Dose Quadrivalent | Vaccine | — | Intramuscular |
| Subject | MRT5421 | Unknown | — | Intramuscular |
| Subject | MRT5424 | Unknown | — | Intramuscular |
| Subject | MRT5429 | Unknown | — | Intramuscular |
| Comparator | Quadrivalent Influenza Standard Dose Vaccine | Vaccine | — | Intramuscular |
Indications
No indication recorded.